LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
30 funds hold it · Insiders net selling
Net selling: insiders sold $4.6M and bought $0 on the open market in 90 days (SEC Form 4). Congress: both buying and selling, $3K to $45K in total in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Oct 29, 2026
Period ending
Sep 30, 2026
Earnings per share
-$0.56 expected
Estimates as of Nov 10, 2026
EPS expected
-$0.77 to -$0.35
Revenue expected
15 analysts
Last 30 days
Split both ways
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Oct 29, 2026 | -$0.42est. -$0.56 | +24.59%beat | $353.2MSEC filing | +192.6%from $120.7M |
| Jun 30, 2026Reported Aug 10, 2026 | -$0.78est. -$0.58 | -33.87%miss | $243.7MSEC filing | +120.4%from $110.6M |
| Mar 31, 2026Reported May 7, 2026 | -$0.84est. -$0.62 | -36.22%miss | $194.5MSEC filing | +66.8%from $116.6M |
| Dec 31, 2025Reported Feb 24, 2026 | -$0.94est. -$0.62 | -50.63%miss | $154.2MAlpha Vantage | +2521.2%from $5.9M |
| Sep 30, 2025Reported Oct 29, 2025 | -$0.72est. -$0.78 | +7.69%beat | $120.7MSEC filing | +4318.0%from $2.7M |
| Jun 30, 2025Reported Aug 5, 2025 | -$0.95est. -$0.60 | -58.33%miss | $110.6MSEC filing | +4999.9%from $2.2M |
| Mar 31, 2025Reported Apr 29, 2025 | -$0.99est. -$0.89 | -11.10%miss | $116.6MSEC filing | -44.8%from $211.1M |
| Dec 31, 2024Reported Feb 20, 2025 | -$1.37est. -$1.09 | -26.09%miss | $5.9MAlpha Vantage | +237.1%from $1.7M |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $154.2M | $194.5M | $243.7M | $353.2M |
| Cost of what it sold | $15.4M | $10.4M | $15.0M | $20.4M |
| Gross profit | $138.8M | $184.1M | $228.6M | $332.7M |
| What it spent | ||||
| Research and development | $142.0M | $126.6M | $149.4M | $143.5M |
| Sales and admin | $158.1M | $163.9M | $186.3M | $200.9M |
| Other operating costs | $23.9M | — | — | — |
| Total operating expenses | $324.0M | $290.0M | $335.7M | $344.4M |
| What was left | ||||
| Operating profit | -$185.2M | -$106.0M | -$107.1M | -$11.6M |
| Interest on debt | $12.0M | $52.8M | $13.3M | $55.5M |
| Profit before tax | -$197.2M | -$166.6M | -$155.9M | -$59.3M |
| Tax | — | — | -$6.2M | $1.2M |
| Net profit | -$197.2M | -$164.0M | -$152.2M | -$56.7M |
| EBITDA | -$183.8M | -$112.6M | -$141.6M | -$2.7M |
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
A 14.2 million-share passive stake links Farallon to BridgeBio Pharma (BBIO).
NeutralNov 12BridgeBio to Present New Acoramidis Data on Kidney Function, Real-World Outcomes, and First-Line Treatment Patterns in ATTR-CM at the International Symposium on Amyloidosis 2026
BullishNov 11What BridgeBio Pharma Holders Bought Into
NeutralNov 11BridgeBio to Participate in November and December Investor Conferences
NeutralNov 9How Investors Are Reacting To BridgeBio Pharma (BBIO) Stronger Quarterly Results
Leans bullishNov 8BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NeutralNov 6BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Leans bullishNov 6BridgeBio Pharma (BBIO) Cut Losses And Grew Revenue, Is The Stock Still Undervalued?
Leans bearishNov 625 macro signals shaping BBIO right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
